GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Regencell Bioscience Holdings Ltd (NAS:RGC) » Definitions » Net Change in Cash

Regencell Bioscience Holdings (Regencell Bioscience Holdings) Net Change in Cash

: $0.00 Mil (TTM As of Jun. 2023)
View and export this data going back to 2021. Start your Free Trial

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Regencell Bioscience Holdings's Net Change in Cash for the six months ended in Jun. 2023 was $0.00 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2023 was $0.00 Mil.

Regencell Bioscience Holdings Net Change in Cash Historical Data

The historical data trend for Regencell Bioscience Holdings's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regencell Bioscience Holdings Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23
Net Change in Cash
0.09 0.14 -0.33 6.36 -4.85

Regencell Bioscience Holdings Semi-Annual Data
Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Net Change in Cash Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.25 - - - -

Regencell Bioscience Holdings Net Change in Cash Calculation

Regencell Bioscience Holdings's Net Change in Cash for the fiscal year that ended in Jun. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-4.963+0.059+0.135+-0.083
=-4.85

Regencell Bioscience Holdings's Net Change in Cash for the quarter that ended in Jun. 2023

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=0+0+0+0
=0.00

Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regencell Bioscience Holdings Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Regencell Bioscience Holdings's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Regencell Bioscience Holdings (Regencell Bioscience Holdings) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Regencell Bioscience Holdings Ltd (NAS:RGC) » Definitions » Net Change in Cash
Comparable Companies
EGRX ALIM ASRT ZOM LFCR OPTN ELTP MRMD ETON AQST ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
N/A
Address
29 Leighton Road, 9/F Chinachem Leighton Plaza, Causeway Bay, Hong Kong, HKG
Website
https://www.regencellbioscience.com
Regencell Bioscience Holdings Ltd is engaged in the research, development and commercialization of traditional Chinese medicine. The medicines are used for the treatment of neurocognitive disorders and degeneration.

Regencell Bioscience Holdings (Regencell Bioscience Holdings) Headlines

From GuruFocus

Regencell Bioscience Holdings Limited Releases CEO Letter to Shareholders

By Business Wire Business Wire • 08-05-2021

Regencell Bioscience Holdings Limited Announces Over $1 Million Ordinary Share Purchase by CEO

By Business Wire Business Wire • 11-22-2021

Regencell Bioscience Holdings Limited Included in the MSCI World Micro Cap Index

By Business Wire Business Wire • 11-22-2021

Regencell Bioscience Holdings Limited Announces Closing of Initial Public Offering

By Business Wire Business Wire • 07-20-2021

Regencell Bioscience Holdings Limited Appoints Dr. William Wing-Yan Lo, JP to its Board of Directors

By Business Wire Business Wire • 12-13-2021

Regencell Bioscience Holdings Limited Establishes a Joint Venture to Offer COVID Treatment

By Business Wire Business Wire • 09-02-2021

Regencell Bioscience Announces Additional EARTH Efficacy Trial Results Corroborating Effectiveness of its Investigational Liquid-Formula RGC-COV19TM in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-Day Treatment Period

By Business Wire Business Wire • 05-18-2022

Regencell Bioscience's Investigational Liquid-Formula RGC-COV19TM Shows Effectiveness Through Its Enrolled Patients in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-day Treatment Period in its EARTH Efficacy Trial

By Business Wire Business Wire • 02-17-2022

Regencell Bioscience Holdings Limited Announces Over $5 Million Ordinary Share Purchases by CEO

By Business Wire Business Wire • 05-16-2022

Regencell Bioscience Holdings Limited Announces Partial Exercise of Underwriter's Over-Allotment Option

By Business Wire Business Wire • 08-20-2021